Weight loss jabs will not be enough to make “lasting progress” on tackling the obesity epidemic, leading medics have said.

Weight loss injections will not be enough to make “lasting progress” in tackling the obesity epidemic, leading medical ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...

Results reveal that weight loss has significant effects on cellular processes that are known to affect metabolic health and ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

The researchers found health perks directly linked with weight loss through blood test results, including increases in HDL ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

A recent survey highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications ...

The mass rollout of weight loss injections on the NHS in England began in June. It means GPs are allowed to prescribe the ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...